🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 19 Sep 2026, 04:26 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42 Clear sponsor filter
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
49 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
DIRECTION- Discontinuation versus continuation of riociguat monotherapy in chronic thromboembolic pulmonary hypertension successfully treated with balloon pulmonary angioplasty
2026-525351-81-00chronic thromboembolic pulmonary hypertension
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
25/08/2026
Phase III
FOSFOLD - Fosfomycin trometamol compared with another active antibiotic relay therapy for the treatment of acute Escherichia coli pyelonephritis in elderly women: a randomized, multicenter, non-inferiority trial
2025-521663-13-00Women aged 75 years or older presenting with E. coli pyelon…
Assistance Publique Hopitaux De Paris
Female Urogenital Diseases and Pregnancy Complications
France
21/08/2026
Phase II
TIPS : Immunomodulatory Treatment of Interstitial Lung Disease Associated with Surfactant related Gene Mutations
2026-525336-41-00Interstitial Lung Disease
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
14/08/2026
Phase II
SDH-FLUX - Development of a new biomarker for tumor development in patients with SDHx mutation by in vivo fluxomics
2023-506001-19-00paraganglioma or pheochromocytoma with surgical indication
Assistance Publique Hopitaux De Paris
Hormonal diseases
France
10/08/2026
Phase III
AVISO - Assessment of Flecainide versus Bisoprolol as First-Line Treatment for Premature Ventricular Contractions: a Multicenter Randomized Clinical Trial
2025-524584-20-00Premature ventricular contractions (PVC)
Assistance Publique Hopitaux De Paris
Cardiovascular Diseases
France
10/08/2026
Phase III
Topical Clobetasol Propionate for Inflammatory Hand osteoarthritis: A randomized trial versus placebo.(PROCLAME)
2025-520678-20-00Adult patients with symptomatic and inflammatory Hand osteo…
Assistance Publique Hopitaux De Paris
Musculoskeletal Diseases
France
07/08/2026
Phase II
VIP-1 : Preclinical type 1 diabetes: the VIP-1 Study
2025-524318-27-00People with stage 1 or stage 2 T1D between the ages of 7 an…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
05/08/2026
Phase III
RUBY study « Randomized controlled trial testing the efficacy of corticosteroid therapy versus placebo in fibrotic hypersensitivity pneumonitis.»
2025-521591-64-00Adult patients with a diagnosis of fibrotic Hypersensitivit…
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
03/08/2026
Phase II
OBINUSS - Safety and efficacy of obinutuzumab in systemic sclerosis: a phase II, randomized, double-blinded versus placebo-controlled trial
2025-524003-68-00Patients with newly or active diffuse Systemic sclerosis at…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
28/07/2026
Phase III
FOSFORMEN : Randomized, multicenter, non-inferiority trial comparing the efficacy of fosfomycin versus fluoroquinolones or cotrimoxazole as oral follow-up treatment in febrile urinary tract infections in men caused by susceptible enterobacteria
2026-525972-25-00Febrile male urinary tract infections caused by Escherichia…
Assistance Publique Hopitaux De Paris
Male Urogenital Diseases
France
16/07/2026
Phase II
Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial (OBLUMEN)
2024-519985-35-00systemic lupus erythematosus pure membranous nephropathy
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
15/07/2026
Phase II
Shared decision-making in uncomplicated appendicitis: a pragmatic randomized trial comparing patient-driven choice (antibiotics only or appendectomy) with systematic appendectomy (FRENCH 47 — ALACARTE trial)
2025-520783-17-01Adult patients diagnosed with uncomplicated acute appendici…
Assistance Publique Hopitaux De Paris
Therapeutics
France
06/07/2026
Phase I
THERIPEX - A phase I/II open label non-randomized study, monocentric, single-arm, evaluating Safety and Efficacy of induced T-CD4 Treg by LV vector transduction expressing the FoxP3 cDNA in patients with IPEX syndrom
2025-523305-15-00Patients affected by IPEX syndrome, proven by molecular di…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
24/06/2026
Phase I/II
ACTIVATE - Phase 1 Clinical Trial evaluating the combination of Actinomycin D and venetoclax in patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2025-524728-22-01Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Assistance Publique Hopitaux De Paris
Not possible to specify
France
10/06/2026
Phase IV
PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANCA (anti-neutrophil cytoplasm antibodies) repositivation in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)
2025-522049-23-00granulomatosis with polyangiitis and microscopic polyangiit…
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
08/06/2026
Phase IV
ANTIMIDIS - Cefazolin mediastinal distribution using microdialysis
2025-521988-13-00Infection prophylaxis
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
05/06/2026
Phase III
MOOD - MethOxyflurane analgesia in vasoOcclusive crises of sickle cell Disease
2024-518043-38-00Sickle cell disease
Assistance Publique Hopitaux De Paris
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
29/05/2026
Phase II
POMREP - Efficacy and safety of zoledronate versus placebo on pain at week 12 in pediatric patients with chronic recurrent multifocal osteomyelitis resistant to non-steroidal anti-inflammatory drug
2023-506420-93-00Chronic recurrent multifocal osteomyelitis (CRMO)
Assistance Publique Hopitaux De Paris
Musculoskeletal Diseases
France
26/05/2026
Phase III
Efficacy of Temocillin compared to standard of care in the Treatment of Neisseria gonorrhoeae Infections: A Multicenter Randomized Controlled Non-Inferiority Trial (TEMtoGo).
2025-524475-23-00Neisseria gonorrhoeae Infections
Assistance Publique Hopitaux De Paris
Bacterial Infections and Mycoses
France
18/05/2026
Phase III
IMMUNOTIME « EVALUATION OF THE EFFECT OF TIME OF ADMINISTRATION ON THE ACTIVITY ON FIRST LINE OF PEMBROLIZUMAB IN ASSOCIATION WITH CARBOPLATIN PEMETREXED IN METASTATIC NON-SQUAMOUS LUNG CANCER. A RANDOMISED MULTICENTER PHASE III TRIAL»
2025-521891-78-00Adult patients with stage IV non squamous non-small cell lu…
Assistance Publique Hopitaux De Paris
Neoplasms
France
12/05/2026
Phase III
MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease
2025-521331-36-00Patient with stabilized SSc-ILD (as defined by a decline of…
Assistance Publique Hopitaux De Paris
Skin and Connective Tissue Diseases
France
11/05/2026
Phase III
ANTIPROM - Comparison of two prophylactic antibiotic regimens in case of preterm prelabor rupture of membranes before 34 weeks of gestation: a randomized controlled trial
2025-520842-31-00Population of study participants Pregnant women with PPROM …
Assistance Publique Hopitaux De Paris
Female Urogenital Diseases and Pregnancy Complications
France
28/04/2026
Phase II
Electrophysiological analysis of Gamma-Hydroxybutyrate-induced sleep in intensive care patients: A Pilot Double-Blind Randomized Controlled Trial.(GAMMA-SLEEP)
2025-521967-11-00The study population includes adult ICU patients with a hos…
Assistance Publique Hopitaux De Paris
Mental Disorders
France
28/04/2026
Phase III
KARMA - INtenSive care TreAtmeNT with adjuvant KetAmine and Recovery after Mechanical ventilAtion: a multicenter doubleblind randomized controlled trial
2025-523149-80-00Adult patients admitted to the ICU and receiving unplanned …
Assistance Publique Hopitaux De Paris
Respiratory Tract Diseases
France
20/04/2026
Phase III
PREV-CART - A multicentric phase III randomized clinical trial open-label, comparing immunoglobulin replacement therapy (IgRT) and antibiotic prophylaxis (AP) in patients treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B cell acute lymphoblastic leukemia or a B cell lymphoma
2025-521571-30-00Young Adults and adults with R/R B-cell acute lymphoblastic…
Assistance Publique Hopitaux De Paris
Hemic and Lymphatic Diseases
France
13/04/2026
Rows per page Showing 1–25 of 49
1 2 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.